Back
Globus Medical 10K Form
Sell
33
GMED
Globus Medical
Last Price:
$59.54
Seasonality Move:
4.41%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-07 | 10Q | GMED/Globus Medical Quarterly |
2023-11-07 | 10Q | GMED/Globus Medical Quarterly |
2023-08-03 | 10Q | GMED/Globus Medical Quarterly |
2023-05-04 | 10Q | GMED/Globus Medical Quarterly |
2022-11-08 | 10Q | GMED/Globus Medical Quarterly |
2022-08-04 | 10Q | GMED/Globus Medical Quarterly |
Receive GMED News And Ratings
See the #1 stock for the next 7 days that we like better than GMED
GMED Financial Statistics
Sales & Book Value
Annual Sales: | $2.5B |
---|---|
Cash Flow: | $136.2M |
Price / Cash Flow: | 16.5 |
Annual Sales: | $30.20 |
Price / Book: | 2.04 |
Profitability
EPS (TTM): | 1.34000 |
---|---|
Net Income (TTM): | $185.6M |
Gross Margin: | $1.5B |
Return on Equity: | 4.59% |
Return on Assets: | 3.71% |
Globus Medical Earnings Forecast
Key Globus Medical Financial Ratios
-
The Gross Profit Margin over the past 16 years for GMED is 58.90%.
-
The Selling, General & Administrative Expenses for GMED have been equal to 38.94% of Gross Profit Margin.
-
The Research & Development expenses have been 6.50% of Revenue.
-
The Interest Expense is -11.22% of Operating Income.
-
The Net Earning history of GMED is 4.09% of Total Revenues.
-
Per Share Earnings over the last 16 years have been positive in 8 years.
Globus Medical Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Health Care Equipment & Supplies |
Sector: | Health Care |
Current Symbol: | GMED |
CUSIP: | 379577 |
Website: | globusmedical.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 4.45 |
Quick Ratio: | 2.6 |
Price-to-Earnings
Trailing P/E Ratio: | 82.13 |
---|---|
Forward P/E Ratio: | 16.66 |
GMED Technical Analysis vs Fundamental Analysis
Sell
33
Globus Medical (GMED)
is a Sell
Is Globus Medical a Buy or a Sell?
-
Globus Medical stock is rated a SellThe current Globus Medical [GMED] share price is $61.60. The Score for GMED is 33, which is 34% below its historic median score of 50, and infers higher risk than normal.